Company news
MoonLake Immunotherapeutics news in 2024
MoonLake Immunotherapeutics's news releases, calls and decks from 2024, newest first.
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
November 12, 2024
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 6, 2024
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
September 8, 2024
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
August 6, 2024
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 9, 2024
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 15, 2024
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 6, 2024
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
April 9, 2024
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
April 9, 2024
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
March 9, 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
March 3, 2024
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
February 28, 2024
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
February 25, 2024
Calls in 2024
Decks in 2024
- Investor Day (March 2024)
Investor day · 102 slides · Mar 11, 2024